Short answer: “LGD-3033” is almost certainly the research SARM LGD-3303 from Ligand Pharmaceuticals; we found no published compound called LGD-3033. LGD-3303 has only been tested in rats: it acted strongly on muscle but only partly on the prostate in castrated rats (Vajda 2009, JPET), and added to the bone benefits of a bisphosphonate in rats with bone loss (Vajda 2009, JBMR). It has never been tested in people, so there is no researched dosage, half-life or human side-effect profile. It is a different compound from LGD-4033 (ligandrol).
What is LGD 3033
LGD-3303 is an orally available nonsteroidal SARM developed by Ligand Pharmaceuticals in San Diego (Vajda 2009, JPET). Products are sold as “LGD-3033” or “LGD-3303”; the published research uses LGD-3303.
| Question | What is known | Evidence |
|---|---|---|
| Muscle | Potent effect on the levator ani muscle in castrated rats | Animal |
| Prostate | Partial agonist: never stimulated the prostate above normal levels, even at high blood concentrations | Animal |
| Bone | Raised bone density in rats with bone loss after ovary removal, and combined with alendronate it was at least as effective, sometimes better | Animal |
| Human data | None | None |
How Does LGD 3033 work?
Like other SARMs, LGD-3303 binds the androgen receptor and switches it on. In castrated rats it kept its muscle-over-prostate selectivity whether it was given by mouth or by continuous infusion, and prostate tissue concentrations were actually higher than muscle concentrations, so the selectivity seems to come from how it acts at the receptor rather than where it goes in the body (Vajda 2009, JPET).
The old version of this page said it works within days, increases water retention for “fuller” muscles and boosts metabolism. None of those claims has a study behind it.
LGD 3033 benefits
The only benefits shown are in rats:
- Muscle: strong effect on a hormone-sensitive muscle in castrated rats (Vajda 2009, JPET).
- Bone: additive bone effects with a bisphosphonate in osteopenic female rats (Vajda 2009, JBMR).
- Fat loss, recovery, strength in people: not studied.
Muscle mass growth, increase in strength and fuller look of muscles
Rat data only: LGD-3303 had potent activity on the levator ani muscle while acting only partly on the prostate (Vajda 2009, JPET). Strength and “fuller muscles” have not been studied.
Fat loss enhancement
Not studied. The old claim that it raises metabolic rate had no source.
Increased bone density
In female rats with bone loss after ovary removal, LGD-3303 combined with the osteoporosis drug alendronate had additive effects on bone (Vajda 2009, JBMR). This has not been tested in people, so it cannot be said to reduce fracture risk.
LGD 3033 side effects
Human side effects are not established: no one has taken LGD-3303 in a published study. The list in the old version of this page (short half-life, raised blood pressure and body temperature) had no source. What can reasonably be expected from its class: SARMs tested in people lowered testosterone and HDL cholesterol (Basaria 2013), and liver injury is the most common serious harm reported with SARMs in healthy adults (Vignali 2023).
Instability due to shorter half-life
The human half-life is not established; the “six hours” in the old version had no source.
Blood pressure increase
Not reported in any study we found.
Body temperature increase
Not reported in any study we found.
Possible cholesterol increase
Not measured for LGD-3303. Other SARMs lowered HDL (“good”) cholesterol in trials; LGD-4033 did so at 1 mg a day.
Possible transient imbalance of testosterone levels
Not measured for LGD-3303. Tested SARMs lowered testosterone in trials, so suppression is likely; bloodwork before and after is the only way to know. See SARMs PCT.
Conclusion
LGD-3033 is most likely LGD-3303, a Ligand research SARM with two rat studies: muscle activity with limited prostate effect, and added bone benefit alongside alendronate. There is no human data, no researched dose or half-life, and no human safety profile. If you are looking at Ligand’s SARMs, LGD-4033 is the one with human trials; compare them in the SARMs database.
Frequently asked questions
What is LGD-3033?
Most likely LGD-3303Evidence: Limited
Most likely a mislabeled name for LGD-3303, a nonsteroidal SARM developed by Ligand Pharmaceuticals. No published compound is called LGD-3033.
What is the LGD-3033 dosage?
No researched human doseEvidence: Animal
LGD-3303 has only been tested in rats. Rat doses cannot be converted into a safe human dose.
What are the benefits of LGD-3303?
Shown only in ratsEvidence: Animal
In rats it showed strong muscle activity with limited prostate stimulation, and added bone benefit when combined with alendronate. No benefit has been shown in people.
Is LGD-3033 the same as LGD-4033?
NoEvidence: Limited
LGD-4033 (ligandrol) is a different Ligand SARM with two human trials; LGD-3303 has only rat data.
What is the half-life of LGD-3033?
Not established in humansEvidence: Limited
No human half-life has been published. The six-hour figure seen online has no published source.
Sources
- Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator
- Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats
- The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men
- Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users